→
Edwards Lifesciences Corp has a market capitalization of $51.90B and a current price of $88.60, reflecting a 2.68% increase from the previous close of $86.29. The company has a P/E ratio of 48.42 and a P/S ratio of 8.55, while experiencing a year-over-year EPS decline of 73.74% alongside revenue growth of 11.55%. The stock has a current ratio of 3.72 and a low D/E ratio of 0.06, indicating solid liquidity and minimal debt exposure.
Investors may consider the diverse factors impacting Edwards Lifesciences' stock performance before making any decisions.
Some investors point to Edwards Lifesciences' projected benefits from the CMS Transcatheter Aortic Valve Replacement Rule, which may enhance revenue streams. Additionally, a 11.55% revenue growth year-over-year suggests strong demand for the company's products in the surgical appliance sector.
Conversely, the company has faced a significant year-over-year EPS decline of 73.74%, raising concerns about profitability. Furthermore, recent insider stock disposals may signal a lack of confidence among company executives regarding future performance.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Edwards Lifesciences Corp has a market capitalization of $51.90B and a current price of $88.60, reflecting a 2.68% increase from the previous close of $86.29. The company has a P/E ratio of 48.42 and a P/S ratio of 8.55, while experiencing a year-over-year EPS decline of 73.74% alongside revenue growth of 11.55%. The stock has a current ratio of 3.72 and a low D/E ratio of 0.06, indicating solid liquidity and minimal debt exposure.
Conversely, the company has faced a significant year-over-year EPS decline of 73.74%, raising concerns about profitability. Furthermore, recent insider stock disposals may signal a lack of confidence among company executives regarding future performance.
Some investors point to Edwards Lifesciences' projected benefits from the CMS Transcatheter Aortic Valve Replacement Rule, which may enhance revenue streams. Additionally, a 11.55% revenue growth year-over-year suggests strong demand for the company's products in the surgical appliance sector.
Some investors point to Edwards Lifesciences' projected benefits from the CMS Transcatheter Aortic Valve Replacement Rule, which may enhance revenue streams. Additionally, a 11.55% revenue growth year-over-year suggests strong demand for the company's products in the surgical appliance sector. Conversely, the company has faced a significant year-over-year EPS decline of 73.74%, raising concerns about profitability. Furthermore, recent insider stock disposals may signal a lack of confidence among company executives regarding future performance.
Edwards Lifesciences Corp has a market capitalization of $51.90B and a current price of $88.60, reflecting a 2.68% increase from the previous close of $86.29. The company has a P/E ratio of 48.42 and a P/S ratio of 8.55, while experiencing a year-over-year EPS decline of 73.74% alongside revenue growth of 11.55%. The stock has a current ratio of 3.72 and a low D/E ratio of 0.06, indicating solid liquidity and minimal debt exposure.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for EW at helmterminal.dev/analyze/EW, updated continuously during US market hours. No signup required.